Lipella Pharmaceuticals Gains FDA Approval, LIPO Stock Skyrockets
Lipella Pharmaceuticals (NASDAQ: LIPO) has secured FDA approval for an Expanded Access Program (EAP) for its investigational oral rinse, LP-310, designed to treat Oral Lichen Planus (OLP). This decision opens up a crucial treatment option for patients suffering from this chronic inflammatory condition, which affects nearly 6 million Americans. What This Means for Patients The … Read more
